BAL PHARMA
Bal Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in BAL PHARMA
Start SIPBal Pharma Share Price
Bal Pharma Investment Rating
-
Master Rating:
-
Bal Pharma has an operating revenue of Rs. 288.36 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 3% needs improvement, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 46%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 11 which is a POOR score indicating inconsistency in earnings, a RS Rating of 20 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 129 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 75 | 70 | 74 | 69 | 67 | 71 | 70 |
| Operating Expenses Qtr Cr | 69 | 64 | 70 | 63 | 61 | 64 | 63 |
| Operating Profit Qtr Cr | 6 | 5 | 3 | 6 | 6 | 7 | 7 |
| Depreciation Qtr Cr | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest Qtr Cr | 3 | 2 | 2 | 2 | 3 | 3 | 3 |
| Tax Qtr Cr | 0 | 0 | 0 | 2 | 0 | 1 | -2 |
| Net Profit Qtr Cr | 1 | 1 | 3 | 1 | 3 | 2 | 4 |
Bal Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 89.12
- 50 Day
- 91.05
- 100 Day
- 93.76
- 200 Day
- 96.63
- 20 Day
- 88.6
- 50 Day
- 91.37
- 100 Day
- 94.32
- 200 Day
- 99.79
Bal Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 90.59 |
| Second Resistance | 91.67 |
| Third Resistance | 92.59 |
| RSI | 47.51 |
| MFI | 58.66 |
| MACD Single Line | -1.09 |
| MACD | -0.73 |
| Support | |
|---|---|
| First Resistance | 88.59 |
| Second Resistance | 87.67 |
| Third Resistance | 86.59 |
Bal Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 11,718 | 740,343 | 63.18 |
| Week | 32,093 | 1,972,436 | 61.46 |
| 1 Month | 20,232 | 1,348,674 | 66.66 |
| 6 Month | 26,487 | 1,497,304 | 56.53 |
Bal Pharma Result Highlights
Bal Pharma Synopsis
NSE-Medical-Diversified
Bal Pharma Ltd belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 280.37 Cr. and Equity Capital is Rs. 14.82 Cr. for the Year ended 31/03/2022. Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368.| Market Cap | 139 |
| Sales | 287 |
| Shares in Float | 0.75 |
| No of funds | 2 |
| Yield | 1.12 |
| Book Value | 1.51 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | 31 |
| Alpha | -0.03 |
| Beta | 1.11 |
Bal Pharma
| Owner Name | Sep-22 | Jun-22 | Apr-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 52% | 52% | 52% | |
| Foreign Portfolio Investors | 0.2% | 0.3% | 0.3% | |
| Individual Investors | 31.48% | 31.45% | 31.3% | |
| Others | 16.32% | 16.25% | 16.4% |
Bal Pharma Management
| Name | Designation |
|---|---|
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Dr. C V Srinivas | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Additional Director |
| Mr. Kotian Chittananda Damodar | Additional Director |
Bal Pharma Forecast
Price Estimates
Bal Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-11-14 | Quarterly Results & ESOP | Inter alia, To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd. a wholly owned subsidiary of the Company. per share(10%)Dividend |
| 2022-08-11 | Quarterly Results | |
| 2022-05-30 | Audited Results & Final Dividend | |
| 2022-04-13 | Preferential issue of shares | |
| 2022-03-09 | Scheme of Amalgamation | Inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd. per share(10%)Dividend |
Bal Pharma FAQs
What is Share Price of Bal Pharma ?
Bal Pharma share price is ₹88 As on 10 December, 2022 | 13:54
What is the Market Cap of Bal Pharma ?
The Market Cap of Bal Pharma is ₹138 Cr As on 10 December, 2022 | 13:54
What is the P/E ratio of Bal Pharma ?
The P/E ratio of Bal Pharma is 42.7 As on 10 December, 2022 | 13:54
What is the PB ratio of Bal Pharma ?
The PB ratio of Bal Pharma is 2.4 As on 10 December, 2022 | 13:54